Shenzhen Bioeasy Financials
| 300942 Stock | 8.48 0.50 5.57% |
Operating Margin 0.0157 | Profit Margin (0.33) | Return On Equity (0.09) |
Shenzhen | Select Account or Indicator |
Understanding current and past Shenzhen Bioeasy Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Shenzhen Bioeasy's financial statements are interrelated, with each one affecting the others. For example, an increase in Shenzhen Bioeasy's assets may result in an increase in income on the income statement.
Please note, the presentation of Shenzhen Bioeasy's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Shenzhen Bioeasy's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Shenzhen Bioeasy's management manipulating its earnings.
Shenzhen Bioeasy Stock Summary
Shenzhen Bioeasy competes with China State, Poly Real, China Vanke, China Merchants, and Huafa Industrial. Shenzhen Bioeasy is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE100004C78 |
| Business Address | No 101, Liuxian |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.bioeasy.com |
| Phone | 86 755 2309 5742 |
You should never invest in Shenzhen Bioeasy without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Shenzhen Stock, because this is throwing your money away. Analyzing the key information contained in Shenzhen Bioeasy's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Shenzhen Bioeasy Key Financial Ratios
Shenzhen Bioeasy's financial ratios allow both analysts and investors to convert raw data from Shenzhen Bioeasy's financial statements into concise, actionable information that can be used to evaluate the performance of Shenzhen Bioeasy over time and compare it to other companies across industries.| Revenue | 254.11 M | ||||
| Gross Profit | 428.03 M | ||||
| EBITDA | (16.9 M) | ||||
| Net Income | (184.91 M) | ||||
| Total Asset | 1.36 B |
Shenzhen Bioeasy Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 619.7M | 652.9M | 1.2B | 1.3B | 1.4B | 869.7M | |
| Retained Earnings | 163.4M | 183.8M | 402.3M | 331.9M | 138.4M | 209.0M | |
| Cash | 420.8M | 374.2M | 339.2M | 247.5M | 481.7M | 337.2M | |
| Other Assets | 11.7M | 10.0M | 28.9M | 41.6M | 47.9M | 50.3M | |
| Net Receivables | 74.2M | 62.3M | 97.2M | 83.9M | 76.1M | 73.0M | |
| Inventory | 31.3M | 61.6M | 93.9M | 100.6M | 31.5M | 55.9M | |
| Other Current Assets | 5.3M | 4.9M | 3.0M | 213.3M | 12.0M | 11.4M | |
| Total Liab | 91.3M | 103.8M | 207.8M | 317.8M | 507.6M | 533.0M | |
| Total Current Assets | 569.7M | 526.1M | 897.6M | 674.4M | 737.7M | 600.8M | |
| Intangible Assets | 1.4M | 44.1M | 42.6M | 42.4M | 41.4M | 27.2M |
Shenzhen Bioeasy Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 13.7M | 8.5M | 31.6M | 12.2M | 7.2M | 14.0M | |
| Interest Expense | 949.8K | 10.6M | 5.3M | 4.1M | 10.6M | 11.2M | |
| Total Revenue | 239.2M | 258.5M | 597.5M | 686.9M | 254.1M | 373.8M | |
| Gross Profit | 173.1M | 181.7M | 426.2M | 388.1M | 126.9M | 242.0M | |
| Operating Income | 105.2M | 75.1M | 268.3M | 137.7M | (66.9M) | (63.5M) | |
| Cost Of Revenue | 66.1M | 76.7M | 171.4M | 298.8M | 127.2M | 131.8M | |
| Income Before Tax | 106.0M | 73.9M | 268.0M | 94.9M | (177.8M) | (168.9M) | |
| Net Income | 92.3M | 65.4M | 236.5M | 83.0M | (184.9M) | (175.7M) |
Shenzhen Bioeasy Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Shenzhen Bioeasy Bio. It measures of how well Shenzhen is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Shenzhen Bioeasy brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Shenzhen had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Shenzhen Bioeasy has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 257.6M | (66.5M) | (35.0M) | (92.0M) | 234.6M | 246.3M | |
| Capital Expenditures | 26.3M | 82.8M | 79.5M | 176.8M | 128.6M | 81.0M | |
| End Period Cash Flow | 440.8M | 374.2M | 339.2M | 247.2M | 481.7M | 378.8M |
Shenzhen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shenzhen Bioeasy's current stock value. Our valuation model uses many indicators to compare Shenzhen Bioeasy value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shenzhen Bioeasy competition to find correlations between indicators driving Shenzhen Bioeasy's intrinsic value. More Info.Shenzhen Bioeasy Biotechnology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Shenzhen Bioeasy by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shenzhen Bioeasy's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Shenzhen Bioeasy Bio Systematic Risk
Shenzhen Bioeasy's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Shenzhen Bioeasy volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Shenzhen Bioeasy Bio correlated with the market. If Beta is less than 0 Shenzhen Bioeasy generally moves in the opposite direction as compared to the market. If Shenzhen Bioeasy Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Shenzhen Bioeasy Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Shenzhen Bioeasy is generally in the same direction as the market. If Beta > 1 Shenzhen Bioeasy moves generally in the same direction as, but more than the movement of the benchmark.
Shenzhen Bioeasy Biotechnology Total Assets Over Time
Shenzhen Bioeasy Thematic Clasifications
Shenzhen Bioeasy Biotechnology is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Shenzhen Bioeasy November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Shenzhen Bioeasy help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Shenzhen Bioeasy Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Shenzhen Bioeasy Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Shenzhen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Shenzhen Bioeasy's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.92 | |||
| Information Ratio | 0.0873 | |||
| Maximum Drawdown | 27.38 | |||
| Value At Risk | (5.43) | |||
| Potential Upside | 5.61 |
Complementary Tools for Shenzhen Stock analysis
When running Shenzhen Bioeasy's price analysis, check to measure Shenzhen Bioeasy's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shenzhen Bioeasy is operating at the current time. Most of Shenzhen Bioeasy's value examination focuses on studying past and present price action to predict the probability of Shenzhen Bioeasy's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shenzhen Bioeasy's price. Additionally, you may evaluate how the addition of Shenzhen Bioeasy to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |